Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microbiome and FMT in ICPI-Induced GI Complications in Cancer
NCT03819296Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2021
- Primary completion
- Oct 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Fecal Microbiota Transplantation Capsule in Colitis and diarrhea, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Difference in stool microbiome pattern at 1 year and Incidence of adverse events of fecal microbiota transplantation at 1 year. Started Feb 2021; status: recruiting.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
Colitisdiarrhea
Beyond the preview
Go deeper on NCT03819296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819296.